MAM
XFOR icon

Martingale Asset Management’s X4 Pharmaceuticals XFOR Stock Holding History

Martingale Asset Management’s Portfolio XFOR Stock Details XFOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-844
Closed -$236K – 1097
2020
Q2 		$236K Buy
+844
New +$231K ﹤0.01% 970

Other funds holding XFOR

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return

Martingale Asset Management's XFOR Position: Q3 2020 in Review

Martingale Asset Management sold out of X4 Pharmaceuticals (XFOR) in Q3 2020, closing a stake of 844 shares — an estimated $236K sold.

Martingale Asset Management first reported a position in XFOR in Q2 2020 and held it in 1 quarter. The position peaked at $236K in Q2 2020. 53 funds tracked by Wall St. Rank hold XFOR as of Q3 2020.

  • Martingale Asset Management reported no remaining X4 Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • Martingale Asset Management sold 844 X4 Pharmaceuticals shares in Q3 2020, an estimated $236K.
  • Martingale Asset Management first reported a position in X4 Pharmaceuticals in Q2 2020 and held it in 1 quarter.
  • Martingale Asset Management's X4 Pharmaceuticals position peaked at $236K in Q2 2020.
  • 53 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q3 2020.

Based on Martingale Asset Management's 13F filing for Q3 2020, filed 12 Nov 2020.